SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

MGNX

MacroGenics, Inc.
BEARISH
Impact 5/10
Horizonimmediate Processed4d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The significant revenue miss and wider-than-expected net loss are likely to pressure the stock near-term. Monitor upcoming clinical data readouts for MGC028 and MGC026 in H1 2027, as pipeline catalysts are the primary value drivers for this clinical-stage biotech.

DirectionBearish
Confidencehigh
Horizonimmediate

Drugs in focus

MGNX drug pipeline →

lorigerlimab

◆ Mixed Named in this press release
Impact
Phase
Phase 2
Time to market
Unknown — the drug is in Phase 2 with no registrational trial announced. If the lower-dose LINNET data in H1 2027 is compelling enough to support a registrational path, a potential BLA filing would likely be at least 2-3 years away.
Next catalyst
None dated

What to watchThe next catalyst is updated LINNET results at a lower 3 mg/kg Q3W dose, expected in H1 2027, positive data could de-risk the safety profile and support registrational discussions, while further safety issues or weak efficacy would likely impair the asset's value. Meanwhile, watch for partnership/licensing interest in lorigerlimab or the broader pipeline (MGC026), and monitor the stock's elevated ~11% short interest (~10.9 days to cover) which could amplify moves on binary events.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$2.20
T+0 close · Nov 12, 2026 · via day close
Latest settled
−1.36%
T+1 · $2.17
Vs SPY
+0.55%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $2.20entry
  2. T+1 · 20h ago −1.36%α +0.55% · $2.17
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MacroGenics reported Q3 2026 revenue of $18.7M, well below the $39.2M consensus, and a GAAP net loss of $20.1M (EPS -$0.32) vs. consensus EPS of -$0.13. The revenue miss was driven by the absence of large milestone payments that boosted the prior-year quarter. The company ended the quarter with $287.7M in cash, extending its runway through 2028, and highlighted pipeline progress with MGC028, MGC026, and lorigerlimab.

Key Financial Metrics

EPS
−$0.32
est −$0.13 · -146.2%
Revenue
$18.7M
est $39.2M · -52.3% · -64.8% YoY
Rating
miss

Key Facts

  • Total revenue of $18.7M for Q3 2026, down 64.8% from $53.0M in Q3 2025, missing the $39.2M consensus.
  • GAAP net loss of $20.1M (EPS -$0.32) vs. net income of $16.8M in Q3 2025; consensus EPS was -$0.13.
  • Cash, cash equivalents and marketable securities of $287.7M as of September 30, 2026, up from $189.9M at year-end 2025; cash runway guidance through 2028.
  • Received $119.6M from sale of GMP manufacturing operations to Bora, $24.5M regulatory milestone from Sanofi, and $10.0M option license payment from Gilead during Q3.
  • Pipeline progress: MGC028 Phase 1 dose escalation completed, MGC026 interim data at ESMO, first patient dosed with MGC030, and lorigerlimab Phase 2 interim results reported.

Financial Impact

Revenue miss of ~$20.5M vs. consensus; net loss of $20.1M vs. consensus loss of ~$8.3M (based on consensus EPS -$0.13 × 63.7M shares).

revenueepsnet income

Risk Factors

  • Revenue heavily dependent on milestone payments; core collaboration revenue declined sharply.
  • Clinical-stage pipeline with no approved products; regulatory and development risks remain high.
  • Stock is volatile (normal daily move 9.6%) and may overreact to the earnings miss.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
64% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402151

Track record

21 reports on MGNX

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
  2. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
  3. Nov 12, 20264d ago Press Release Bearish 5/10 Viewing Entry $2.20 Now $2.17 +1.36% settles Feb 11
  4. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  5. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  6. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  7. Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  9. Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
  10. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026